Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PDE5A | O76074 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.35 |
| ▸ | PRCP | P42785 | 1/20 | 0.35 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | GCK | P35557 | 1/20 | 0.33 |
| ▸ | BCL2 | P10415 | 1/20 | 0.33 |
| ▸ | BECN1 | Q14457 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1983248 | 1.00 | ALDH1A1 (0.41) | ALDH1A1MAPTLMNAPDE5AHSD11B1 | |
| SCHEMBL1987265 | 0.93 | ALDH1A1 (0.41) | ALDH1A1MAPTLMNAPDE5AUCHL1 | |
| SCHEMBL1987266 | 0.93 | ALDH1A1 (0.41) | ALDH1A1MAPTLMNAPDE5AUCHL1 | |
| SCHEMBL1984714 | 0.89 | PRCP (0.35) | PRCPUCHL1USP30 | |
| SCHEMBL1984716 | 0.89 | PRCP (0.35) | PRCPUCHL1USP30 | |
| SCHEMBL2793620 | 0.88 | ALDH1A1 (0.43) | ALDH1A1MAPTLMNAUCHL1USP30 | |
| SCHEMBL2793622 | 0.88 | ALDH1A1 (0.43) | ALDH1A1MAPTLMNAUCHL1USP30 | |
| SCHEMBL2367420 | 0.86 | NPC1 (0.49) | LMNAUCHL1USP30 | |
| SCHEMBL2367426 | 0.86 | NPC1 (0.49) | LMNAUCHL1USP30 | |
| SCHEMBL1983019 | 0.86 | NPC1 (0.49) | LMNAUCHL1USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150218194-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2015-08-06 | — | — | US | disclosed |
| US-9006387-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2015-04-14 | — | — | US | disclosed |
| EP-2853531-A2 | Antiviral compounds | AbbVie Bahamas Ltd. (BS) | 2015-04-01 | — | — | EP | disclosed |
| US-20140315792-A1 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES | 2014-10-23 | — | — | US | disclosed |
| EP-2337781-B1 | ANTI-VIRAL COMPOUNDS TO TREAT HCV INFECTION | ABBVIE BAHAMAS LTD (BS) | 2014-07-23 | — | — | EP | disclosed |
| EP-2368890-B9 | Hepatitis C virus inhibitors | ABBVIE BAHAMAS LTD (BS) | 2013-10-30 | — | — | EP | disclosed |
| EP-2628481-A1 | Trisubstituted heterocycles as replication inhibitors of hepatitis C virus HCV | AbbVie Bahamas Ltd. (BS) | 2013-08-21 | — | — | EP | disclosed |
| EP-2368890-B1 | Hepatitis C virus inhibitors | ABBVIE BAHAMAS LTD (BS) | 2013-04-17 | — | — | EP | disclosed |
| EP-2455376-A1 | Heterocyclic compounds as inhibitors of hepatitis C virus (HCV) | Abbott Laboratories (US) | 2012-05-23 | — | — | EP | disclosed |
| EP-2368890-A1 | Hepatitis C virus inhibitors | Abbott Laboratories (US) | 2011-09-28 | — | — | EP | disclosed |
| EP-2337781-A2 | ANTI-VIRAL COMPOUNDS TO TREAT HCV INFECTION | Abbott Laboratories (US) | 2011-06-29 | — | — | EP | disclosed |
| US-20100317568-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2010-12-16 | — | — | US | disclosed |
| WO-2010144646-A2 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317568-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | ALDH1A1 2858/4885MAPT 2833/4885LMNA 3118/4885 |
| US-20140315792-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | ALDH1A1 2858/4885MAPT 2833/4885LMNA 3118/4885 |
| US-20150218194-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | ALDH1A1 2858/4885MAPT 2833/4885LMNA 3118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.